ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY), a biopharmaceutical company focused on protecting patients from severe allergic reactions, has announced its participation in the 2024 Cantor Global Healthcare Conference in New York City from September 17-19, 2024. The company's leadership, including Richard Lowenthal (Co-Founder, President, and CEO) and Eric Karas (Chief Commercial Officer), will engage in a fireside chat on September 17 at 9:10 a.m. ET.

Additionally, management will conduct one-on-one meetings with investors during the conference. The fireside chat will be accessible via live webcast on the company's website, with a replay available for 90 days in the Investors & Media section.

News Market Reaction – SPRY

+4.26%

1 alert

+4.26% News Effect

On the day this news was published, SPRY gained 4.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Cantor Global Healthcare Conference being held September 17-19, 2024 in New York City.

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Tuesday, September 17, 2024, at 9:10 a.m. ET. Company management will also participate in one-on-one meetings with investors.

A live webcast of the fireside chat will be available here and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy in the EU) (previously referred to as ARS-1), an epinephrine nasal spray for patients with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.

ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com

ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com

FAQ

When is ARS Pharmaceuticals (SPRY) participating in the Cantor Global Healthcare Conference?

ARS Pharmaceuticals (SPRY) is participating in the Cantor Global Healthcare Conference from September 17-19, 2024, in New York City.

Who will represent ARS Pharmaceuticals (SPRY) at the 2024 Cantor Global Healthcare Conference?

Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will represent ARS Pharmaceuticals (SPRY) at the conference.

What type of presentation will ARS Pharmaceuticals (SPRY) give at the 2024 Cantor conference?

ARS Pharmaceuticals (SPRY) will participate in a fireside chat on Tuesday, September 17, 2024, at 9:10 a.m. ET.

Will there be a webcast of ARS Pharmaceuticals' (SPRY) presentation at the Cantor conference?

Yes, a live webcast of the fireside chat will be available on the company's website, with a replay archived for 90 days in the Investors & Media section.

What is the focus of ARS Pharmaceuticals (SPRY) as a company?

ARS Pharmaceuticals (SPRY) is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis.